×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VCYT – veracyte, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VCYT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
02:12 pm
vcyt
Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks? [Yahoo! Finance]
Low
Report
Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks? [Yahoo! Finance]
12/16
01:22 pm
vcyt
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave [Yahoo! Finance]
Low
Report
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave [Yahoo! Finance]
12/11
01:28 pm
vcyt
Those who invested in Veracyte (NASDAQ:VCYT) a year ago are up 68% [Yahoo! Finance]
Neutral
Report
Those who invested in Veracyte (NASDAQ:VCYT) a year ago are up 68% [Yahoo! Finance]
12/5
04:13 pm
vcyt
Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines [Yahoo! Finance]
Low
Report
Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines [Yahoo! Finance]
12/5
04:05 pm
vcyt
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
Medium
Report
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
12/5
08:01 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) had its "neutral" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $37.00 price target on the stock, down previously from $38.00.
Low
Report
Veracyte, Inc. (NASDAQ: VCYT) had its "neutral" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $37.00 price target on the stock, down previously from $38.00.
11/18
10:31 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) had its price target raised by analysts at Morgan Stanley from $26.00 to $28.00. They now have an "underweight" rating on the stock.
Low
Report
Veracyte, Inc. (NASDAQ: VCYT) had its price target raised by analysts at Morgan Stanley from $26.00 to $28.00. They now have an "underweight" rating on the stock.
11/15
08:28 am
vcyt
Veracyte, Inc. (NASDAQ: VCYT) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $50.00 price target on the stock.
Medium
Report
Veracyte, Inc. (NASDAQ: VCYT) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $50.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/17
04:31 pm
vcyt
Form 4 VERACYTE, INC. For: Dec 13 Filed by: Stapley Marc
Medium
Report
Form 4 VERACYTE, INC. For: Dec 13 Filed by: Stapley Marc
12/13
04:27 pm
vcyt
Form 144 VERACYTE, INC. Filed by: Stapley Marc
Low
Report
Form 144 VERACYTE, INC. Filed by: Stapley Marc
12/6
04:35 pm
vcyt
Form 4 VERACYTE, INC. For: Dec 04 Filed by: McGuire Annie
Low
Report
Form 4 VERACYTE, INC. For: Dec 04 Filed by: McGuire Annie
12/6
04:35 pm
vcyt
Form 4 VERACYTE, INC. For: Dec 04 Filed by: Febbo Phillip G.
Low
Report
Form 4 VERACYTE, INC. For: Dec 04 Filed by: Febbo Phillip G.
12/5
05:25 pm
vcyt
Form 144 VERACYTE, INC. Filed by: Febbo Phillip G.
Low
Report
Form 144 VERACYTE, INC. Filed by: Febbo Phillip G.
12/4
05:00 pm
vcyt
Form 4 VERACYTE, INC. For: Dec 02 Filed by: Leite John
Low
Report
Form 4 VERACYTE, INC. For: Dec 02 Filed by: Leite John
12/4
05:00 pm
vcyt
Form 4 VERACYTE, INC. For: Dec 02 Filed by: Chambers Rebecca
Low
Report
Form 4 VERACYTE, INC. For: Dec 02 Filed by: Chambers Rebecca
12/4
05:00 pm
vcyt
Form 4 VERACYTE, INC. For: Dec 02 Filed by: McGuire Annie
Low
Report
Form 4 VERACYTE, INC. For: Dec 02 Filed by: McGuire Annie
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Form 4 VERACYTE, INC. For: Mar 20 Filed by: Anderson Bonnie H
16.7%
3/25 Form SEC STAFF LETTER VERACYTE, INC. 15.6%
2/29 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
12/4 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 7.9%
4/24 Form DEFA14A VERACYTE, INC. 7.9%
6/27 Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019 7.5%
8/12 Form 4 VERACYTE, INC. For: Aug 09 Filed by: JONES EVAN/ FA 6.7%
10/26 Veracyte Inc (NASDAQ: VCYT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $29.00 price target on the stock. 6.5%
4/7 Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations 6.3%
10/19 Veracyte Inc (NASDAQ: VCYT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $29.00 price target on the stock. 6.1%
3/25 Form SEC STAFF LETTER VERACYTE, INC. 15.6%
2/29 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
12/4 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 7.9%
4/24 Form DEFA14A VERACYTE, INC. 7.9%
6/27 Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019 7.5%
8/12 Form 4 VERACYTE, INC. For: Aug 09 Filed by: JONES EVAN/ FA 6.7%
10/26 Veracyte Inc (NASDAQ: VCYT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $29.00 price target on the stock. 6.5%
4/7 Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations 6.3%
10/19 Veracyte Inc (NASDAQ: VCYT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $29.00 price target on the stock. 6.1%
TOP News Decliners
4/1
Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients
-16.6%
3/11 Form 4 VERACYTE, INC. For: Mar 10 Filed by: Anderson Bonnie H -16.1%
10/22 Veracyte Announces Third Quarter 2019 Financial Results and Business Progress -15.7%
8/13 Form 4 VERACYTE, INC. For: Aug 12 Filed by: Anderson Bonnie H -8.2%
2/21 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -8.1%
10/24 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -7.3%
9/3 Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer -7.1%
8/1 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -6.8%
7/30 Form 10-Q VERACYTE, INC. For: Jun 30 -6.7%
4/14 Form 8-K VERACYTE, INC. For: Apr 13 -6.3%
3/11 Form 4 VERACYTE, INC. For: Mar 10 Filed by: Anderson Bonnie H -16.1%
10/22 Veracyte Announces Third Quarter 2019 Financial Results and Business Progress -15.7%
8/13 Form 4 VERACYTE, INC. For: Aug 12 Filed by: Anderson Bonnie H -8.2%
2/21 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -8.1%
10/24 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -7.3%
9/3 Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer -7.1%
8/1 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -6.8%
7/30 Form 10-Q VERACYTE, INC. For: Jun 30 -6.7%
4/14 Form 8-K VERACYTE, INC. For: Apr 13 -6.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: